Estimands and Their Role in Clinical Trials

被引:44
|
作者
Akacha, Mouna [1 ]
Bretz, Frank [1 ,2 ]
Ohlssen, David [3 ]
Rosenkranz, Gerd [2 ]
Schmidli, Heinz [1 ]
机构
[1] Novartis Pharma AG, Stat Methodol & Consulting, CH-4002 Basel, Switzerland
[2] Med Univ Vienna, Ctr Med Stat Informat & Intelligent Syst, Vienna, Austria
[3] Novartis Pharmaceut, Stat Methodol & Consulting, E Hanover, NJ USA
来源
关键词
Estimand; ICH E9 guideline; Missing data; Sensitivity analysis; MISSING DATA; PERSPECTIVE; IMPUTATION;
D O I
10.1080/19466315.2017.1302358
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
The National Research Council (NRC) highlighted the need to more clearly distinguish between the target of estimation (estimand) and the method of estimation (estimator) in clinical trials. While the NRC report on The Prevention and Treatment of Missing Data in Clinical Trials focuses on issues arising due to missing data, a framework to coherently align trial objectives and corresponding estimands is valuable in a broader sense. The International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) has reinforced this by tasking a working group to develop an addendum to the ICH-E9 guideline Statistical Principles for Clinical Trials. In this article, we motivate the need for change, propose a structured framework to bridge trial objectives with proper inference tools, and discuss how it may impact the role of statisticians involved in clinical trial design and analysis.
引用
收藏
页码:268 / 271
页数:4
相关论文
共 50 条
  • [21] Estimands for overall survival in clinical trials with treatment switching in oncology
    Manitz, Juliane
    Kan-Dobrosky, Natalia
    Buchner, Hannes
    Casadebaig, Marie-Laure
    Degtyarev, Evgeny
    Dey, Jyotirmoy
    Haddad, Vincent
    Jie, Fei
    Martin, Emily
    Mo, Mindy
    Rufibach, Kaspar
    Shentu, Yue
    Stalbovskaya, Viktoriya
    Tang, Rui
    Yung, Godwin
    Zhou, Jiangxiu
    PHARMACEUTICAL STATISTICS, 2022, 21 (01) : 150 - 162
  • [22] Translating questions to estimands in randomized clinical trials with intercurrent events
    Stensrud, Mats J.
    Dukes, Oliver
    STATISTICS IN MEDICINE, 2022, 41 (16) : 3211 - 3228
  • [23] Response to comments on 'sensitivity of estimands in clinical trials with imperfect compliance'
    Chen, Heng
    Heitjan, Daniel F.
    INTERNATIONAL JOURNAL OF BIOSTATISTICS, 2024, 20 (02): : 433 - 433
  • [24] Estimands: bringing clarity and focus to research questions in clinical trials
    Clark, Timothy Peter
    Kahan, Brennan C.
    Phillips, Alan
    White, Ian
    Carpenter, James R.
    BMJ OPEN, 2022, 12 (01):
  • [25] Why estimands are needed to define treatment effects in clinical trials
    Keene, Oliver N.
    Lynggaard, Helle
    Englert, Stefan
    Lanius, Vivian
    Wright, David
    BMC MEDICINE, 2023, 21 (01)
  • [26] Estimands in hematologic oncology trials
    Sun, Steven
    Weber, Hans-Jochen
    Butler, Emily
    Rufibach, Kaspar
    Roychoudhury, Satrajit
    PHARMACEUTICAL STATISTICS, 2021, 20 (04) : 793 - 805
  • [27] Reflections on estimands for patient-reported outcomes in cancer clinical trials
    Lawrance, Rachael
    Skaltsa, Konstantina
    Regnault, Antoine
    Floden, Lysbeth
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2023,
  • [28] The potential of the estimands framework for clinical pharmacology trials: Some discussion points
    Ring, Arne
    Wolfsegger, Martin J.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 86 (07) : 1240 - 1247
  • [29] Comments on "sensitivity of estimands in clinical trials with imperfect compliance" by Chen and Heitjan
    Baker, Stuart G.
    Lindeman, Karen S.
    INTERNATIONAL JOURNAL OF BIOSTATISTICS, 2024,
  • [30] Choosing Appropriate Estimands in Clinical Trials (Leuchs et al): Letter to the Editor
    Garrett, Andrew
    THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2015, 49 (04) : 601 - 601